Abbott and Dexcom,two leaders in the continuous glucose monitor market,today struck a settlement agreement for ongoing patent litigation.

雅培和Dexcom這兩(liang) 家連續血糖監測儀(yi) 市場的領先企業(ye) 今天就正在進行的專(zhuan) 利訴訟達成了和解協議。

Our sibling site,Drug Delivery Business News,reports today that the companies settled all outstanding patent disputes between them.

我們(men) 的兄弟網站Drug Delivery Business News今天報道說，這兩(liang) 家公司解決(jue) 了它們(men) 之間所有懸而未決(jue) 的專(zhuan) 利糾紛

The patent litigation relates to the companies’continuous glucose monitor(CGM)technologies.The companies and Dexcom are two leaders in the CGM space.They offer market-leading platforms,with Abbott’s FreeStyle Libre 3 and Dexcom’s G7 representing their latest-generation technologies.

專(zhuan) 利訴訟與(yu) 兩(liang) 家公司的連續血糖監測儀(yi) (CGM)技術有關(guan) 。這兩(liang) 家公司和Dexcom是CGM領域的兩(liang) 大領軍(jun) 企業(ye) 。它們(men) 提供市場領先的平台，雅培的FreeStyle Libre 3和Dexcom的G7代表了它們(men) 最新一代的技術。

News of the settlement comes within a few weeks of a Unified Patent Court decision that sided with Abbott following a CGM patent infringement claim from Dexcom.Dexcom requested that the court find infringement with the LibrelinkUp remote analyte monitoring system.The court revoked EP282 in its entirety across the contracting member states in Europe as specified by Abbott’s request.It dismissed all of Dexcom’s infringement claims based on the patent at issue.

在Dexcom提出CGM專(zhuan) 利侵權索賠後的幾周內(nei) ，統一專(zhuan) 利法院做出了支持雅培的判決(jue) ，雅培與(yu) Dexcom達成和解的消息不脛而走。Dexcom要求法院認定LibrelinkUp遠程分析監測係統侵權。法院根據雅培的請求，在歐洲各簽約成員國全麵撤銷了EP282。法院駁回了Dexcom基於(yu) 涉案專(zhuan) 利提出的所有侵權索賠。